Top 10 Companies in the (R)-1-Phenylpropylamine (CAS 3082-64-2) Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

Global (R)-1-Phenylpropylamine (CAS 3082-64-2) market size was valued at USD 28.4 million in 2025. The market is projected to grow from USD 30.1 million in 2026 to USD 52.7 million by 2034, exhibiting a 6.5% annual growth rate during the forecast period.

(R)-1-Phenylpropylamine (CAS 3082-64-2) is a chiral amine compound – specifically the (R)-enantiomer of 1-phenylpropylamine – widely recognized for its role as a chiral resolving agent and key building block in asymmetric synthesis. Its well‑defined stereochemical configuration makes it particularly valuable in the production of pharmaceutically active compounds, where enantiomeric purity is critical to both efficacy and safety. The compound finds primary application in the synthesis of active pharmaceutical ingredients (APIs), agrochemicals, and fine chemicals.

The market is steadily gaining traction, motivated by the growing pharmaceutical industry’s emphasis on enantioselective drug development and the rising global demand for chiral intermediates. Furthermore, increasing investments in asymmetric synthesis technologies and expanding R&D activities across contract research and manufacturing organizations (CROs and CMOs) are reinforcing demand. Key suppliers operating in this space include Sigma‑Aldrich (Merck KGaA), TCI Chemicals, and Alfa Aesar, among other fine chemical manufacturers with established chiral chemistry portfolios.

(R)-1-Phenylpropylamine (CAS 3082-64-2) Market – View in Detailed Research Report

---

1️⃣ 1. Enamine LLC

Headquarters: Kyiv, Ukraine

Key Offering: Scalable asymmetric synthesis of high‑purity chiral amines.

Enamine’s portfolio includes (R)-1‑phenylpropylamine that is routinely employed as an API intermediate. The company’s integrated synthesis platform delivers consistent enantiomeric excess, making it a preferred partner for early‑stage drug discovery and late‑stage synthesis.

Sustainability Initiatives:

• Investment in green chemistry protocols to reduce hazardous waste.
• Implementation of digital quality management for real‑time process monitoring.
• Rapid turnaround for custom purity specifications.
• Commitment to GMP‑compliant production across all facilities.

---

2️⃣ 2. Combi-Blocks Inc.

Headquarters: Boston, USA

Key Offering: Modular chiral building block library.

Combi‑Blocks supplies a curated catalog of (R)-1‑phenylpropylamine with ready‑to‑use enantiomeric purity, facilitating rapid route design for API synthesis. The company’s library approach shortens lead times for new compound development.

Sustainability Initiatives:

• Use of renewable feedstocks in synthesis streams.
• Closed‑loop process design to minimize waste.
• Carbon‑neutral manufacturing footprint.
• Transparent reporting of environmental metrics.

---

3️⃣ 3. Apollo Scientific Ltd.

Headquarters: London, UK

Key Offering: High‑purity chiral intermediates for pharmaceutical and fine‑chemical applications.

Apollo delivers (R)-1‑phenylpropylamine with stringent optical purity, supporting both small‑batch research and large‑scale API production. The firm’s analytical capabilities enable rapid verification of purity and stereochemistry.

Sustainability Initiatives:

• Carbon‑neutral manufacturing processes.
• Water recycling systems to reduce consumption.
• Lean production techniques that lower energy use.
• Partnerships with suppliers to source sustainable raw materials.

---

4️⃣ 4. Oakwood Products, Inc.

Headquarters: Cincinnati, USA

Key Offering: Industrial‑grade chiral amines.

Oakwood supplies (R)-1‑phenylpropylamine for agrochemical synthesis and process chemistry. The company’s large‑scale production capacity ensures a reliable supply for high‑volume customers.

Sustainability Initiatives:

• Energy‑efficient synthesis routes that lower CO₂ emissions.
• Low‑VOC process designs to protect worker safety.
• Compliance with local environmental regulations.
• Continuous improvement programs to reduce resource consumption.

---

5️⃣ 5. Biosynth AG

Headquarters: Basel, Switzerland

Key Offering: Advanced chiral synthesis platforms.

Biosynth delivers (R)-1‑phenylpropylamine with ultra‑high enantiomeric excess, ideal for complex therapeutics that demand exceptional stereochemical control.

Sustainability Initiatives:

• Zero‑waste processes that recycle solvents and reagents.
• Use of renewable catalysts to reduce environmental impact.
• GMP‑ready production lines for pharmaceutical use.
• Strategic R&D collaborations to accelerate green chemistry.

---

6️⃣ 6. TCI America

Headquarters: New York, USA

Key Offering: Fine‑chemical catalog for research and pilot scale.

TCI America provides (R)-1‑phenylpropylamine as part of its extensive catalog, enabling researchers to prototype synthetic routes quickly.

Sustainability Initiatives:

• ISO‑9001 certification ensures quality and process control.
• Waste reduction strategies across production.
• Fast turnaround times for custom orders.
• Detailed analytical data supporting regulatory submissions.

---

7️⃣ 7. Alfa Chemistry

Headquarters: Philadelphia, USA

Key Offering: High‑purity chiral intermediates.

Alfa supplies (R)-1‑phenylpropylamine to pharmaceutical and research clients, emphasizing batch consistency and optical purity.

Sustainability Initiatives:

• Lean manufacturing that reduces material waste.
• Recyclable solvent systems to lower environmental footprint.
• Robust quality management for regulatory compliance.
• Continuous monitoring of energy usage.

---

8️⃣ 8. Synthonix, Inc.

Headquarters: San Diego, USA

Key Offering: Custom chiral synthesis.

Synthonix offers tailored (R)-1‑phenylpropylamine for niche applications, providing flexibility in purity and scale.

Sustainability Initiatives:

• Modular processes that adapt to changing demand.
• Carbon‑footprint reduction through efficient resource use.
• Rapid prototyping for early‑stage development.
• Scalable production pathways that maintain quality.

---

9️⃣ 9. Pharmaffiliates Analytics & Synthetics

Headquarters: Mumbai, India

Key Offering: Cost‑effective chiral intermediates.

Pharmaffiliates delivers (R)-1‑phenylpropylamine for generic drug development, emphasizing competitive pricing without compromising purity.

Sustainability Initiatives:

• Local sourcing of raw materials to reduce transportation emissions.
• Waste minimization programs across production lines.
• Regional manufacturing that supports supply chain resilience.
• Strategic partnerships to enhance process efficiency.

---

🔟 10. Sigma‑Aldrich (Merck KGaA)

Headquarters: Darmstadt, Germany

Key Offering: Extensive fine‑chemical portfolio.

Sigma‑Aldrich supplies (R)-1‑phenylpropylamine for API synthesis, leveraging its global distribution network to meet diverse customer needs.

Sustainability Initiatives:

• Green chemistry programs that reduce hazardous waste.
• Energy‑efficient production facilities.
• High‑purity products that support regulatory compliance.
• Collaborative R&D to advance sustainable synthesis.

Download FREE Sample Report

(R)-1-Phenylpropylamine (CAS 3082-64-2) Market – View in Detailed Research Report

---

Outlook to 2034

The (R)-1‑phenylpropylamine market is expected to maintain a steady upward trajectory, driven by sustained demand from the pharmaceutical sector and expanding applications in agrochemicals and fine chemicals. Regional shifts toward Asia‑Pacific manufacturing are anticipated to enhance supply chain resilience, while continued investment in asymmetric catalysis is likely to lower production costs and broaden market penetration.

---

Emerging Trends

• Integration of continuous flow chemistry to improve yield and scalability.
• Adoption of biocatalytic routes that offer superior selectivity and lower energy consumption.
• Digitalization of supply chain logistics to provide real‑time inventory visibility.
• Growing emphasis on green chemistry, including solvent recycling and renewable feedstocks.
• Expansion of custom synthesis services to support niche therapeutic development.